In this fifth update to the living guidelines on drugs for the treatment of COVID-19, the World Health Organization analyzed results of clinical trials that assessed the effects of casirivimab-imdevimab and corticosteroids in patients with severe and non-severe disease.
Researchers say eyes with a Boston keratoprosthesis type 1 that underwent glaucoma surgery earlier had better visual outcomes.
A study says the supplements can reduce the need for intravitreal bevacizumab injections among patients with nonproliferative diabetic retinopathy and macular edema.
Researchers reviewed the potential for diagnosis and staging with ocular thermography.
A study shows visual acuity 6 months after endophthalmitis following keratoprosthesis implantation correlates with pre-endophthalmitis acuity.
Many patients developed irreversible blindness, according to the report.
A study links the rare corneal disorder and variants in the TMEM45A gene.
Systemic immunosuppression also elevated the risk, researchers found.
Patients with uveitis of an infectious etiology also experienced more detachment.
Standardizing these criteria may aid in both clinical research and to supplement subjective clinical assessments.
